They have antimicrobial, anti-inflammatory, anti-fibrotic and immune-modulatory properties. They can serve as novel therapeutic options for Inborn Errors of Metabolism (IEM). They can also treat acute organ failures and chronic organ deteriorations that cannot otherwise benefit from transplants requiring life-long immunosuppression.
Our team has a history of delivering results for patients. We are deeply committed to putting patients first in everything we do. Tandem is comprised of global leaders with extensive IEM based bench-to-bedside translational expertise, as well as a track record for delivering groundbreaking therapies. As founders of TBI we aim to capitalize on our proprietary discoveries and leverage the inherent benefits of perinatal stem cells to generate much-needed and safe allogeneic cellular treatments.
With 20+ years of experience in developing medical nutrition products, as the former founder, president, and CEO of Cambrooke Therapeutics (formerly Cambrooke Foods), David has built and managed a multinational research, manufacturing, and commercialization company serving the IEM community. Now a wholly owned subsidiary of Ajinomoto Corp. David remains a board member and consultant to the company.
With 25+ years of experience in drug discovery and development in IEM, Christineh is a seasoned technology executive with extensive bench-to-bedside experience in pharmaceutical/biotech research. Her work formed the basis for the FDA approved drug Palynziq (2018); she has also advanced several first-in-class therapies into the clinic.
With 20+ years of experience in stem cell-based strategies for the treatment of acute and congenital liver disease, Roberto has a broad background in medical genetics and translational medicine, as well as unique expertise in human liver and placental stem cell research, clinical transplantation and biotherapeutic conversion.
Interested in what we do at Tandem Biotherapeutics? Please drop us a line by filling out the form below and a member of our team will get back to you.